camptothecin has been researched along with 2-acetylfuranonaphthoquinone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bando, H; Iino, S; Kadowaki, S; Kageyama, R; Kawazoe, A; Masuishi, T; Muro, K; Taniguchi, H; Yoshino, T | 1 |
Bendell, J; Cervantes, A; Chiu, VK; Fakih, M; Falcone, A; Fontaine, M; Grothey, A; Hitron, M; Oh, SC; Shah, MA; Tabernero, J; Taieb, J; Tebbutt, NC; Tomasek, J; Van Cutsem, E; Wu, C; Xu, B; Xu, RH; Yamaguchi, K; Yoshino, T | 1 |
2 trial(s) available for camptothecin and 2-acetylfuranonaphthoquinone
Article | Year |
---|---|
Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Bevacizumab; Camptothecin; Colorectal Neoplasms; Humans; Japan; Leucovorin; Naphthoquinones | 2021 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms | 2023 |